Experimental drug shows early promise against tough blood cancers
NCT ID NCT05526313
Summary
This first-in-human study tested a new drug called Purinostat Mesylate (PM) in 29 adults with advanced blood cancers that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see how the drug moves through the body. Early lab studies suggested the drug could target cancer cells, but this trial was primarily about safety, not proving effectiveness in people.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.